Literature DB >> 8795133

Tiagabine and non-convulsive status epilepticus.

G Schapel1, D Chadwick.   

Abstract

Three patients who developed clinical evidence of non-convulsive status epilepticus while on high doses of the investigational antiepileptic drug, tiagabine are reported. This apparently paradoxical phenomenon developed when the tiagabine dose was increased to 48 mg/day in one patient, and to 60 mg/day in two other patients, in combination with other antiepileptic drugs. Seizure control improved following reduction in tiagabine dose in one patient and discontinuation of tiagabine in the two others. The observation raises the possibility of a clinically relevant paradoxical epileptogenic effect of GABA-ergic drugs such as tiagabine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795133     DOI: 10.1016/s1059-1311(96)80111-7

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  15 in total

Review 1.  Typical absence seizures and their treatment.

Authors:  C P Panayiotopoulos
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Ictal epileptiform activity is facilitated by hippocampal GABAA receptor-mediated oscillations.

Authors:  R Köhling; M Vreugdenhil; E Bracci; J G Jefferys
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-23       Impact factor: 3.000

Review 4.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Tiagabine for acute affective episodes in bipolar disorder.

Authors:  Akshya Vasudev; Karine Macritchie; Sanjay K Rao; John Geddes; Allan H Young
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 6.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 7.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 8.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 9.  Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.

Authors:  J C Adkins; S Noble
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

10.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.